<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90765748-00A7-4D14-9C5F-F34DA45F3D55"><gtr:id>90765748-00A7-4D14-9C5F-F34DA45F3D55</gtr:id><gtr:name>Western University</gtr:name><gtr:address><gtr:line1>Western University Main Campus</gtr:line1><gtr:line2>#3, Street 528</gtr:line2><gtr:line3>Sangkat Boeung Kok I, Khan Tuol Kork</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90765748-00A7-4D14-9C5F-F34DA45F3D55"><gtr:id>90765748-00A7-4D14-9C5F-F34DA45F3D55</gtr:id><gtr:name>Western University</gtr:name><gtr:address><gtr:line1>Western University Main Campus</gtr:line1><gtr:line2>#3, Street 528</gtr:line2><gtr:line3>Sangkat Boeung Kok I, Khan Tuol Kork</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C3992259-C19F-4FE5-9C01-210C819D7264"><gtr:id>C3992259-C19F-4FE5-9C01-210C819D7264</gtr:id><gtr:name>Yale University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/102F2A51-71E4-4ECA-A245-9B9C4858D7E4"><gtr:id>102F2A51-71E4-4ECA-A245-9B9C4858D7E4</gtr:id><gtr:name>MRC Harwell</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AAB94755-0482-44D0-86B2-C6EFDB5C36C7"><gtr:id>AAB94755-0482-44D0-86B2-C6EFDB5C36C7</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Abraham</gtr:surname><gtr:orcidId>0000-0001-8952-6057</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7C1D2F98-5F68-4B69-934B-3B0DCA6B9093"><gtr:id>7C1D2F98-5F68-4B69-934B-3B0DCA6B9093</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Denton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D742E9B1-A4F5-4657-80DD-F6293C03A7F7"><gtr:id>D742E9B1-A4F5-4657-80DD-F6293C03A7F7</gtr:id><gtr:firstName>George</gtr:firstName><gtr:surname>Bou-Gharios</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801052"><gtr:id>4C06B742-3775-4D02-AAB3-CDE0084383CA</gtr:id><gtr:title>Genetic models for connective tissue disease, scarring and fibrosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801052</gtr:grantReference><gtr:abstractText>When vital organs are damaged in disease this results in the development of scar tissue. When the scar is excessive or disporportionate this can itself worsen organ function, a process termed fibrosis. Fibrosis is a result of altered or abnormal healing processes and is a common factor in many common diseases. Less common disorders such as scleroderma (also called systemic sclerosis) cause fibrois in multiple organs including the skin, lungs, heart and blood vessels. We have developed, for the first time, models of fibrotic disease that can be used to study the development and consequences of fibrosis in the skin and internal organs. Through understanding these models, it is very likely that better methods for assessment and treating fibrosis will emerge.</gtr:abstractText><gtr:technicalSummary>Fibrosis occurs due to excessive or inappropriate deposition of extracellular matrix in affected tissues. Systemic sclerosis is an uncommon rheumatic disease in which susceptibility to skin and visceral fibrosis leads to high mortality and morbidity. Key fibrotic mediators have been identified in SSc, including TGFbeta and CTGF. It is likely that overactivity of these mediators, or their downstream pathways, underlies the development of fibrosis in SSc and that this may also be relevant to other forms of fibrotic disease. We have developed 3 unique mouse models of fibrotic disease that recapitulate cardinal features of SSc including skin and lung fibrosis and vasculopathy. We will use these models to extend and validate molecular and imaging strategies that complement those used in human disease. The first model uses fibroblast-specific expression of a non-signalling type II TGFbeta receptor to increase constitutive TGFbeta activity in connective tissue in a ligand-dependent fashion. This leads to skin fibrosis and increased susceptibility to lung injury. The second mouse strain permits conditional fibroblast-specific high level activation of TGFbeta signalling that is ligand independent. A Cre-Lox strategy is used for fibroblast specific expression of a constitutively active mutant type I TGFbeta receptor. This strain develops marked skin and vascular fibrosis. A hallmark of both of these mouse stains is upregulation of CTGF. In the third model we have overexpressed CTGF in fibroblasts and again observe a severe skin fibrosis. 
Together these complementary strains will be used to explore development of SSc associated autoantibodies and to ask whether the gene and protein expression in affected mouse organs replicates that of human SSc. A comparison of markers from these mouse models with those from scleroderma patients should increase our understanding of the diverse disease phenotypes of human scleroderma. In addition we will translate recent clinical advances in SSc assessment into these mouse strains, including novel imaging modalities, to provide a platform for future testing of targeted anti-fibrotic therapies.</gtr:technicalSummary><gtr:fund><gtr:end>2012-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>474266</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCB Celltech</gtr:department><gtr:description>UCL FLARRE Consortium</gtr:description><gtr:id>D876461E-9567-43FE-B0A0-931E41FD9E05</gtr:id><gtr:impact>This partnership has just begun and aimed at indentifying common pathways to fibrosis.</gtr:impact><gtr:outcomeId>agJ3jFayem4-1</gtr:outcomeId><gtr:partnerContribution>UCB celltech have co-funded a PhD studentship</gtr:partnerContribution><gtr:piContribution>We have developed a Consortiun at UCL in inflammation, tissue repair, scarring and fibrosis with the aim of promoting partnerships with Industry</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Biosciences</gtr:department><gtr:description>microCT analysis of murine lung</gtr:description><gtr:id>A33F2B61-33E7-4041-873A-6A8E69470A99</gtr:id><gtr:impact>This collaboration has resulted in a new skill-set within our group and has also formed the basis of a manuscript which is in preparation.
This collaboration is multi-disciplinary as it brings together the biology of lung structure and fibrosis and the physics of microCT scanning and the use of non-invasive imaging to assess extent of lung fibrosis.</gtr:impact><gtr:outcomeId>KwCKN7VKQ6m-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators have allowed access to their microCT system. They have also provided their expertise in the technique and given training and assistance in the use of the scanner and analysis of the data collected.</gtr:partnerContribution><gtr:piContribution>We have provided the models for this study to examine the use of non-invasive imaging in the asessment of pulmonary fibrosis in mice. We have also performed all stages of the experimental and preparation tissue and analysis of the data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Inflammation and Therapeutic Innovation</gtr:department><gtr:description>Centre for Inflammation and Therapeutic Innovation (CiTI) QMUL</gtr:description><gtr:id>148C4B3A-3129-4257-AF36-6C275FF98646</gtr:id><gtr:impact>Formation of the multidiscinplinary UCLPartners (UCL/QMUL) - UCB Pharma joint PhD programme</gtr:impact><gtr:outcomeId>58c6f8177cc222.87546758-1</gtr:outcomeId><gtr:partnerContribution>- Development of the London Inflammation Network
- Provides a framework for synergy across UCLPartners (QMUL and Barts Health NHS Trust / UCL and associated Foundation Trusts) as well as attracting external academic and industrial partners. 
- Contributes to exploiting therapeutic innovation alongside bioengineering and biomaterials opportunities and technical innovation within the unifying process of inflammation
- Harness multi-disciplinary knowledge and know how across UCLPartners for developing innovative therapeutic approaches for patients with inflammatory and autoimmune diseases and societal benefit.</gtr:partnerContribution><gtr:piContribution>The new multi-disciplinary Centre for Inflammation and Therapeutic Innovation (CiTI) at Queen Mary University of London (QMUL) presents a unique opportunity for a strategic partnership aimed at exploring, endorsing, developing and testing innovative strategies for anti-inflammatory therapies with a two-way bench to bedside (and backward) approach. Citi is linked to the UCL FLARRE consortium and is develop strategic alliances in inflammation biology and tissue repair between UCLPartners and the Bio-Pharma sector</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Yale University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Internal Medicine</gtr:department><gtr:description>UCL-YALE Collaboration</gtr:description><gtr:id>A3608716-1C7B-4F94-9D09-FB69D1A0DCB6</gtr:id><gtr:impact>The aims of the Yale-UCL Collaboration are to:


? Identify areas of scientific interest between faculties working on fibrosis.

? Identify common resources and complementary technologies. 

? Evaluate international granting opportunities. 

? Develop infrastructure to secure NIH, RCUK and Biomedical Charity funding

? Engage in strategic alliances with the commercial sector (Pharma and Biotech)</gtr:impact><gtr:outcomeId>53874e1fe3da58.66025366-1</gtr:outcomeId><gtr:partnerContribution>Hosted a Fibrosis Symposium and have co-developed the frame-work for a UCL-YALE Fibrosis Consortium</gtr:partnerContribution><gtr:piContribution>Provided Lectures on the Yale Fibrosis Symposium and co-developed the frame-work for a UCL-YALE Fibrosis Consortium, and have developed a linked website.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Western University</gtr:collaboratingOrganisation><gtr:country>Canada</gtr:country><gtr:department>Schulich School of Medicine &amp; Dentistry Western Ontario</gtr:department><gtr:description>The role of PTEN in fibrosis</gtr:description><gtr:id>BD7DB447-8E4E-4809-9DAB-49163FF3C7B8</gtr:id><gtr:impact>This collaboration has resulted in the publication of a paper:
Parapuram, S.K., Xu, S., Elliott, C., Welch, I.D., Jones, H., Baron, M., Denton, C.P., Abraham, D.J., and Leask, A. (2011) Loss of PTEN expression by dermal fibroblasts causes skin fibrosis. JID 131: 1996-2003</gtr:impact><gtr:outcomeId>JpNJaEKK1ux-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators have provided access to a further genetic murine model of fibrosis (conditional PTEN knockout). Analysis of this model has been performed collaboratively by the two groups.</gtr:partnerContribution><gtr:piContribution>We have performed in vitro analysis to complement the in vivo analysis which we have performed collaboratively towards elucidating the mechanisms involved in the contribution to fibrosis made by the loss of P-I-3 kinase/AKT regulator PTEN</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Analysis of anti-nuclear auto-antibodies</gtr:description><gtr:id>07453DB3-2E20-4F79-9D77-465D0CABC9EF</gtr:id><gtr:impact>We are building up a picture of the autoantibody profiles on the mouse models to comapre with the profiles in the human disease</gtr:impact><gtr:outcomeId>FGi8Gv9WZxJ-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators have provided their expertise in the identification of anti-nuclear auto-antibodies. They also performed the screening of our murine sera.</gtr:partnerContribution><gtr:piContribution>We provided the murine sera from genetically-modified mice for analysis of auto-antibody profiles. We have also performed statistical analysis of the data collected</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>MRC Harwell</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Mammalian Genetics Unit</gtr:department><gtr:description>MRC Mouse Network - International Mouse Phenotyping Consortium (IMPC)</gtr:description><gtr:id>A84A0B04-EBD7-4828-8DA1-FADC5BDD167E</gtr:id><gtr:impact>The main activites within this consortium are to phenotype ~100 conditional knock-out mice provied by the MRC Network in organ-based models of scarring and fibrosis. In year one, 21 prioritize genes have been submitted to the Mouse Network for initial study.</gtr:impact><gtr:outcomeId>kpLvmanVaCX-1</gtr:outcomeId><gtr:partnerContribution>Provision of novel conditional knock-out mice under the consortium title: Tissue Repair and Fibrosis.</gtr:partnerContribution><gtr:piContribution>The key contributions thus far are:
- Development of a UK-wide consortium focusing on organ-based Tissue Repair and Fibrosis.
- Co-ordination of all members to provied a comprehensive gene list within the initiative
- Prioritisation of the 'first' gene set for study
- Development fo objectives and targets within the consortium.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Psychiatry, Psychology &amp; Neuroscience</gtr:department><gtr:description>MRI analysis of murine skin</gtr:description><gtr:id>7DEEF89F-4E32-4AD5-9977-F128835BD19A</gtr:id><gtr:impact>This collaboration has resulted in presentations at national and international conferences.
This collaboration is multi-disciplinary as it brings together the biology of skin structure, histological analysis and the physics of MRI analysis.</gtr:impact><gtr:outcomeId>i8iCYFXyhTm-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators have allowed access to their MRI system. They have also provided their expertise in the technique and have assisted with the data collection.</gtr:partnerContribution><gtr:piContribution>We have provided the murine models for study and prepared the samples for scanning. We have analysed the data collected and performed histological analysis of the samples post-scanning to validate the MRI technique for analysis of skin fibrosis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Hospital News Letter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B15F18ED-3CB2-4242-BBC7-AFA94A6C6113</gtr:id><gtr:impact>Twice yearly news letters (Spring and Winter) are sent our to ~4,000 patients and their relative. News letters cover the research and clincial activities taking place in the Department, and major advances as well as new staff recruitments, new awards for research and new and exciting areas of study.

Feed back in terms of correspondcne to the Department, visits to the laboratories and attendance at our once-a-year open day.</gtr:impact><gtr:outcomeId>LU2e2j43K6w</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.scleroderma-royalfree.org.uk/</gtr:url><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wellcome Trust - Fibrosis Meeting:  Tissue Fibrosis: State-of-the-Art and Overcoming Roadblocks to Translation</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>648ED7F8-AEDF-4BD9-B91C-8AFFD8153AAA</gtr:id><gtr:impact>Fibrosis , the formation of excess fibrous connective tissue, is a global health concern. In response to repetitive injury or inflammation, this pathological scarring process ultimately leads to disordered tissue architecture and impairment of organ function. The meeting was highly interactive discussing fibrosis, models of fibrosis, discovering meaningful biomarkers, matrix biology, potential immunological targets and current challenges in the field.

Development of a UK wide Network for Fibrosis
Setting up a a Web-based portal 'Technology Expertise Sharing Network'</gtr:impact><gtr:outcomeId>5464950a7c27b9.12195848</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>https://www.wellcometrustevents.org/WELLCOME/media/uploaded/EVWELLCOME/event_305/Final%20agenda%20-%20Tissue%20Fibrosis%208%20and%209%20September%202014.pdf</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Department web-site</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D8FEA767-B8A8-43FC-95D3-E384E7DCA008</gtr:id><gtr:impact>In addition to the UCL web-site and Royal Free NHS Trust we have developed our own web-site to disseminate rearch advances to the wider comunity. NHS links

The web-site, http://www.scleroderma-royalfree.org.uk/ recives ~300 hits per month and has direct links to UCL and NHS sityes and other relevant sites of including Patient societies/charities.</gtr:impact><gtr:outcomeId>pjxCJwKU6Tb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.ucl.ac.uk/medicine/</gtr:url><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>FLARRE Consortium</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A8BF9626-51AE-4F70-8F1C-511E327852DC</gtr:id><gtr:impact>The vision is to promote emerging talent and innovation whilst tackling the key questions relevant to fibrosis and inflammation through investigation, invention and collaboration with industry. The FLARRE Consortium aims to increase understanding of these diseases to ultimately lead to patient benefit.


Promoted the development of a UCL cluster of expertise in fibrosis and infammation. Highlight multidisciplinary skills and promote synergy across UCL. Identify and promote emerging talent (PhD students and young investigators)at UCL. Augment commercial engagement and develop interaction with industry. Enhance international academic collaborations</gtr:impact><gtr:outcomeId>SGMHQiidxw2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ucl.ac.uk/flarre</gtr:url><gtr:year>2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hospital Open Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>22BC3B94-89E5-4CE4-B4F9-4E10D97E8104</gtr:id><gtr:impact>Attended by ~100 people including the public, patients and their relatives, patient groups and other health porfessionals including Doctors and Nurses and Occupational Therapists.

Patients and their relatives and members of the public visited the laboratory</gtr:impact><gtr:outcomeId>fo7t97vhMkb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.scleroderma-royalfree.org.uk/</gtr:url><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCL-Boehringer Ingelheim PhD Studentship</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>85BAF7E3-8E35-40FA-AEAA-8B7B1E4172D0</gtr:id><gtr:outcomeId>54648133eff253.11592341</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>89000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship/UCL Grand Challenge</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>C8B108EA-ABF3-44E9-8E7F-85BE651C951A</gtr:id><gtr:outcomeId>adkaRtHm7x80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>190000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Resarch UK project grant (DA-Co-App; PI - Blandine Poulet)</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>20717</gtr:fundingRef><gtr:id>E9811A1A-BE79-44A5-9D0C-044BF9607EB5</gtr:id><gtr:outcomeId>58c6f4ed4707f4.74254660</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Rosetrees Trust</gtr:fundingOrg><gtr:id>8FB5D5CB-746B-4891-9F0E-8B5F8FBDFE65</gtr:id><gtr:outcomeId>e4aBfrqdu46</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>89000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship/UCL Grand Challenge</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>C5352E37-7262-4FC5-AB12-C7F8D5436EBB</gtr:id><gtr:outcomeId>L29fhVkXYEB0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Studentship/UCL/UCB Celltech Impact Award</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>University College London</gtr:fundingOrg><gtr:id>CFD22D16-1E9C-4000-8F10-1C323004C548</gtr:id><gtr:outcomeId>fe1aCg8TzAk1</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>124374</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant - Remodeling in PAH</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>828C736D-3E49-4E27-98F8-DB5A83B24F84</gtr:id><gtr:outcomeId>rzbq47YATWP0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>350000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Career Development Fellowship (DA Supervisor; Fellow Blandine Poulet)</gtr:description><gtr:end>2020-12-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:fundingRef>20859</gtr:fundingRef><gtr:id>2F13BC01-3E64-41A0-8D74-E06178CC6A38</gtr:id><gtr:outcomeId>58c6f4251f8e80.00386014</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>220000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant - Fibrocytes in scleroderma</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>F. Hoffmann-La Roche AG</gtr:fundingOrg><gtr:id>B0C2CB7F-76B5-40F2-A5F4-7970C4D45D4F</gtr:id><gtr:outcomeId>aDhqGdAa28f0</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>410875</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Raynaud's &amp;amp; Scleroderma Association (RSA) Programme Grant</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Raynaud's &amp; Scleroderma Association</gtr:fundingOrg><gtr:id>EE12CE03-880C-4168-8D68-E7D4A4A457F8</gtr:id><gtr:outcomeId>Xk7MneJeDL10</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>820000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Programme grant (DA Co-Applicant; PI Prof Adrian Hobbs)</gtr:description><gtr:end>2021-08-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>RG/16/7/32357</gtr:fundingRef><gtr:id>E704F6FF-3C8F-478F-A8F9-E7D010BE3FEB</gtr:id><gtr:outcomeId>58c6f33babe7e4.24529218</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99224</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant - EMT in Scleroderma</gtr:description><gtr:end>2012-08-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>DD0CA034-9284-4E53-8A6C-C100CF4C968A</gtr:id><gtr:outcomeId>hqiDiGVaxgR0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The present inventors found when investigating gene expression in OcMMP fibroblasts that aldehyde dehydrogenase 1 family member A3 (ALDH1A3) is up regulated in OcMMP. Elevated expression of ALDH1A3 was then confirmed by quantitative polymerase chain reaction (qPCR) and protein levels were assessed by western blot. In view of this surprising finding, aldehyde dehydrogenase inhibitors were added to OcMMP fibroblasts, which resulted in the restoration of phenotype and function to control cell levels. These results suggest that inhibition of aldehyde dehydrogenase using aldehyde dehydrogenase inhibitors should provide an effective therapy for treating or preventing fibrosis. Accordingly, the present invention provides an aldehyde dehydrogenase inhibitor for use in the treatment or prevention of fibrosis. The invention further provides use of an aldehyde dehydrogenase inhibitor in the manufacture of a medicament for treating or preventing fibrosis. The invention further provides a method for treating or preventing fibrosis in a patient in need thereof, the method comprising adminstering to said patient an aldehyde dehydrogenase inhibitor. The invention further provides a cosmetic method for treating scarring in response to an injury in a subject, the method comprising administering an aldehyde dehydrogenase inhibitor to the subject.</gtr:description><gtr:grantRef>G0801052</gtr:grantRef><gtr:id>7309368B-E49B-491F-A524-167E05F00352</gtr:id><gtr:impact>Studies have implicated inhibition of aldehyde dehydrogenase as a potential therapy for treating or preventing fibrosis in mucous membrane pemphigoid (MMP), particularly ocular mucous membrane pemphigoid (OcMMP), pulmonary fibrosis, scleroderma, idiopathic pulmonary fibrosis, cystic fibrosis, cirrhosis, endomyocardial fibrosis, myocardial infarction, atrial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis, Crohn's disease, keloids, arthrofibrosis, Peyronie's disease, Dupuytren's contracture and adhesive capsulitis Liver fibrosis as well as cirrhosis, atherosclerosis, cardiac fibrosis, pulmonary and peripheral vascular disease.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>53875c73a9c495.68400414</gtr:outcomeId><gtr:patentId>N402793GB</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>TREATMENT AND/OR PREVENTION OF FIBROSIS</gtr:title></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A unique mechanism leading to remodelling of the blood vessels</gtr:description><gtr:grantRef>G0801052</gtr:grantRef><gtr:id>AFCC419B-3EA9-49EB-9E8D-CF9D22246E79</gtr:id><gtr:impact>We have received further funding in terms of proof-of concept to carry out extensive pre-clinical in vivo studies to develop the field.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>FfHKQZuV5DA</gtr:outcomeId><gtr:patentId>1212773.4</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Vascular Remodelling</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MSc/MRes Human Tissue Repair</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D852513A-375C-4029-B825-59F0A17F16CB</gtr:id><gtr:outcomeId>58c6f9208eaee2.11791956</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.ucl.ac.uk/medicine/study/postgraduate-taught-degrees/msc-mres-human-tissue-repair</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MSc Module in Advanced Rheumatology</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>47C6F526-7BBA-43B5-9C2E-41BBCE63C314</gtr:id><gtr:outcomeId>pd5ynWd5GuE</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Contribution to undergraduate degree in Applied Medical Sciences</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>73B4F3BC-78C7-4E88-8FF1-C1092F1CF559</gtr:id><gtr:outcomeId>54649d338bc161.22692749</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.ucl.ac.uk/prospective-students/undergraduate/degrees/ubsmedsapp05</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Acquisition of a hypoxic chamber for animal in vivo work used promarily as a model for human disease pulmonary arterial hypertension (PAH).</gtr:description><gtr:id>896A603D-3BC0-48F8-BBE5-2DA2C2DC9BE0</gtr:id><gtr:impact>Facilitated the development of a research programe aimed at investigation molecular pathways and drug discovery in PAH</gtr:impact><gtr:outcomeId>pSHza66RxMU</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Hypoxic Chamber</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:url>http://www.coylab.com/</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have optimized a method for assessing murine lung fibrosis using microCT</gtr:description><gtr:id>085C004A-5902-4197-9EB8-22AF74FE1E38</gtr:id><gtr:impact>Data collected from microCT analysis of murine lungs forms the basis of a manuscript which is in preparation</gtr:impact><gtr:outcomeId>EwB7kUocxJc</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>microCT assessment of murine lung fibrosis</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have optimized a method for assessing murine dermal fibrosis using MRI</gtr:description><gtr:id>9C0073A8-07B2-4D83-AE96-94652C7F20DA</gtr:id><gtr:impact>This technique has been presented at national and international conferences</gtr:impact><gtr:outcomeId>efYfr4NrBD7</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MRI assessment of skin fibrosis</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AD6F4AAE-003C-411A-A8E9-27399FFE0DAF</gtr:id><gtr:title>Connective tissue growth factor causes EMT-like cell fate changes in vivo and in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8eb5a0435d8d3373b79ad83bc88fd42e"><gtr:id>8eb5a0435d8d3373b79ad83bc88fd42e</gtr:id><gtr:otherNames>Sonnylal S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>pm_13952_22_23525012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>761C99CC-7F3E-484A-8461-1FE50AF1DF8A</gtr:id><gtr:title>Aldehyde dehydrogenase inhibition blocks mucosal fibrosis in human and mouse ocular scarring.</gtr:title><gtr:parentPublicationTitle>JCI insight</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63b49cf3bbd0e61af8a6a9e32dc06734"><gtr:id>63b49cf3bbd0e61af8a6a9e32dc06734</gtr:id><gtr:otherNames>Ahadome SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2379-3708</gtr:issn><gtr:outcomeId>583d5e38d3da51.38728059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9198A73-973E-4363-AE3C-B44913D39D70</gtr:id><gtr:title>A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f4ed81ee88fdfaba076662620bf318a1"><gtr:id>f4ed81ee88fdfaba076662620bf318a1</gtr:id><gtr:otherNames>Shiwen X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56594d17820692.63240463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CB05234-D1E9-47D2-8F4C-F49BF55A19D1</gtr:id><gtr:title>Endothelial injury in a transforming growth factor ?-dependent mouse model of scleroderma induces pulmonary arterial hypertension.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e2ded8aafde280d50a3b26508cdc471"><gtr:id>2e2ded8aafde280d50a3b26508cdc471</gtr:id><gtr:otherNames>Derrett-Smith EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>pm_13952_22_23839959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF855B68-E6CF-41FD-8137-F66212E137AD</gtr:id><gtr:title>Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78bfa66073c16496f680efbd100cb149"><gtr:id>78bfa66073c16496f680efbd100cb149</gtr:id><gtr:otherNames>Nikitorowicz-Buniak J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>54647fefbf9ce7.24278394</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F873D21A-4FC0-4055-9EAD-35ED59D518CA</gtr:id><gtr:title>Loss of PTEN expression by dermal fibroblasts causes skin fibrosis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa71a3a5a305c56d319d8585e4811e83"><gtr:id>fa71a3a5a305c56d319d8585e4811e83</gtr:id><gtr:otherNames>Parapuram SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>i6G8K2XENEd</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801052</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>